## ## |Mr
I C Martin|Chair|||| |---|---|---|---|---| |Dr D G Mason|Honorary Treasurer|||| |Mrs J Barber||||| |Dr P J Greaves|Honorary Treasurer (elect)|||| |Professor TJ Hendra||||| |Professor Sir 8 Keogh||||| |Professor
N Kumar|Appointed|4'"January 2022||| |Dr 5 Lishman
CBE||||| |Professor
M Sani|Appointed|4'"January 2022||| |The principal address ofthe charity and the registered|||office ofthe company|isthe offices of NCEPOD at Abbey House, 74-| |76StJohn Street, London, EC1M 4DZ.||||| ## ## ## ## |Association ofAnaesthetists|||Royal College ofOphthalmologists| |---|---|---|---| |Dr W Fawcett|||Vacancy| |Association ofSurgeons of|Great Britain and Ireland||Royal College of Paediatrics
and Child Health| |Mr M Lansdown|||Dr I Doughty| |Royal College of Emergency|Medicine||Royal College of Physicians of London| |Dr A Boyle|||Dr A Gibson, Dr M Kumwenda
and Dr H Skene| |Faculty of Dental Surgery|||Royal College of Physicians
and Surgeons of Glasgow| |Mr J Dhanda|||Dr M McKirdy —moved to observer status 4 Nov 21| |Faculty of Intensive
Care Medicine|||Royal College of Physicians of Edinburgh| |Dr J Butler|||Dr J MacLeod —moved to observer status 4 Nov 21| |Lay Representatives|||Royal College of Psychiatrists| |Vacancy|||Vacancy| |Royal College of Anaesthetists|||Royal College of Radiologists| |Dr C Carey and Dr K Ramachandaran|||Prof R McWilliams| |Royal College of General Practitioners|||Royal College of Pathologists| |Vacancy|||Dr L Igali| |Royal College of Nursing|||Royal College ofSurgeons of Edinburgh| |Dr N Ashby|||Miss A Paisley —moved to observer status 4 Nov 21| |Royal College ofObstetricians||and Gynaecologists|Royal College ofSurgeons of England| |DrT Hillard|||Miss SVig| |Twelve consultants|had been on secondment|to|NCEPOD as Clinical Co-ordinators|NCEPOD as Clinical Co-ordinators|between|1April 2021 and|31 March| |---|---|---|---|---|---|---|---| |2022, committing|to between
one and two sessions|||per week.|||| |Dr M Docherty|Liaison Psychiatry||||||| |Dr A Goodwin|Anaesthesia
and Critical Care||||||| |Dr M Juniper|Respiratory
Medicine||||||| |Dr K Malbon|Paediatrics||||||| |Dr SMcPherson|Radiology||||||| |Dr D McWilliams|Physiotherapy
—appointed|||in March 22|||| |Dr A Michalski|Paediatric
Oncology||||||| |Mr M Sinclair|General Surgery||||||| |Dr V Srivastava|Acute Medicine||||||| |Dr ATavare|General Practice||||||| |Dr K Wilkinson|Paediatric Anaesthesia||—left in October 21||||| |Mr J Abercrombie|Surgery||||||| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## |Area ofstudy:||||Milestone reached:| |---|---|---|---|---| |Physical healthcare|in mental|health|hospitals|Report is due for release 14/4/22| |Epilepsy||||Data being reviewed| |Crohn's disease||||Cases being reviewed| |Community
acquired|pneumonia|||Data collection just starting| |Transition
between|child and|adult|healthcare|Cases being reviewed| |Endometriosis||||Study being developed| |End of life care||||Study being developed| |Testicular torsion||||Study being developed| |Natural
deaths
in prison||||Data collection underway| |Juvenile arthritis||||Study being developed| |Blood sodium||||Study being developed| |ICU rehabilitation||||Study being developed| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## |Year ending 31March 2|022|||| |---|---|---|---|---| ||||Total|Total| |||Notes|2022|2021| ||||E|E| |INCOME FROM:||||| |Donations|||132,900|12,000| |Charitable
activities|||1,243,871|1,154,353| |Investments|||6,741|10,303| |TOTAL INCOME|||1,383,512|1,176,656| |EXPENDITURE ON:||||| |Charitable
activities|||1,216,165|972,248| |TOTAL EXPENDITURE|||1,216,165|972,248| |Net gain on investments|||11,311|34,820| |NET INCOME|||178,658|239,228| |NET MOVEMENT IN FUNDS|||178,658|239,228| |RECONCILIATION
OF FUNDS||||| |Fund balances brought|forward|||| |at 1April 2021|||1,515,571|1,276,343| |FUND BALANCES CARRIED FORWARD||||| |AT31MARCH 2021|||1,694,229|1,515,571| ## ## |||Notes|2022|2021| |---|---|---|---|---| ||||f|f| |FIXEDASSETS||||| |Tangible assets|||838|3,292| |Investments|||223,849|212,538| ||||224,687|215,830| |CURRENT ASSETS||||| |Debtors|||376,339|355,757| |Cash at bank and in|hand||1,264,869|1,091,609| ||||1,641,208|1,447,366| |LIABILITIES||||| |Creditors: Amounts|falling due within one year|10|(171,666)|(147,625)| |NET CURRENT ASSETS|||1,469,542|1,299,741| |TOTAL ASSETS LESS|CURRENT LIABILITIES|||| |& NET ASSETS|||1,694,229|1,515,571| |THE FUNDS OF THE|CHARITY|||| |Unrestricted
income|funds|||| |General
Fund|||1,664,229|1,495,571| |Designated
Premises|Fund||30,000|20,000| |TOTAL CHARITY FUNDS|||1,694,229|1,515,571| ## |REGISTERED COMPANY N|O. 030|19382||||| |---|---|---|---|---|---|---| |CASH FLOWS||||||| |Year ending 31March 2022||||||| |||||Notes|2022|2021| ||||||f|E| |Cash flows from operating|activities|||||| |Net cash provided
by operating||activities||13|167,023|338,206| |Cash flows from investing|activities|||||| |Interest from investments|||||6,741|10,303| |Purchase oftangible fixed|assets||||(504)|(1,737)| |Receipts from sale ofinvestments||||||174,875| |Purchase ofinvestments||||||(200,637)| |Net cash (outflow) inflow|from|investing|activities||6,237|(17,196)| |Increase (decrease) in cash for the year|||||173,260|321,011| |Cash brought forward|||||1,091,609|770,598| |Cash carried forward||||||| ||||||1,264,869|1,091,609| ## ## ## ## ## ## ## ## ## ## ## ## ## ## |NATIONAL
CONFIDENTIAL
ENQUIRY INTO PATIENT OUTCOME AND DEATH| |---| |REGISTERED COMPANY NO. 03019382| |ACCOUNTING
POLICIES| |Year ending 31March 2022| ## ## |O THE FINANCIAL STATE
ng 31March 2022|MENTS||| |---|---|---|---| |||Total|Total| |||2022|2021| |||f|f| |DONATIONS:|||| |Donated services||132,900|12,000| |||132,900|12,000| |INCOME FROM CHARITABLE ACTIVITIES- DESIGNING AND RUNNING||CONFIDENTIAL SURVEY|| |Healthcare
Quality Improvement||1,207,221|1,091,234| |Partnership
(HQIP)|||| |Private hospitals||30,650|49,800| |Conference,
exhibition|and other||| |income sources||6,000|13,319| |||1,243,871|1,154,353| |INVESTMENT INCOME|||| |Dividends||6,079|8,161| |Bank interest receivable|on||| |short term cash deposits||662|2,142| |||6,741|10,303| ## |||||Total|Total| |---|---|---|---|---|---| |||||2022|2021| |||||f|f| |Support costs (note 5)||||241,369|244,142| |Direct staff costs (note|6)|||574,354|515,358| |Other direct expenditure:|||||| |Staff healthcare,
training,
and recruitment||||2.337|1,441| |Clinical co-ordinators
secondments||||217,746|177,881| |Clinical reviewers
(donated services)||||132,900|12,000| |Clinical co-ordinators,|reviewers,|and|||| |staff expenses||||14,757|6,508| |Consultancy||||13,235|2,009| |Temporary
staff costs||||4,696|| |Conference, exhibition,|and meetings||||| |expenses||||371|(2,325)| |Operating
lease rentals:|||||| |Plant and machinery||||7,247|5,666| |Other printing
and report production|||costs|4,782|5,536| |Postage and distribution||||2,371|4,032| |||||1,216,165|972,248| |O THE FINANCIAL STATEMENT
ng 31March 2022|S||||| |---|---|---|---|---|---| |||Support|Governance|Total|Total| |||costs|costs|2022|2021| |||f|E|E|E| |SUPPORT AND GOVERNANCE|COSTS||||| |Staff costs (note 6)|||746|746|691| |Other expenditure:|||||| |Operating
lease rentals:|||||| |Land and buildings||133,644||133,644|136,747| |Other premises costs||22,521||22,521|15,854| |Auditors'
remuneration:|||||| |Audit fees|||8,100|8,100|10,288| |Bookkeeping
and payroll costs||9,352|14|9,366|11,086| |Public relations||859|1|860|454| |Computer
expenses
Insurance||21,919
20,562|32
30|21,951
20,592|31,127
17,635| |Sundry expenses
Telephone
Office costs||6,054
4,741
8,933|11
7
14|6,065
4,748
8,947|4,247
4,536
5,400| |Steering Group expenses||680|1|681|| |Trustee expenses|||||| |Depreciation
—owned assets||2,954||2,958|5,934| |Bank charges||190||190|143| |||232,410|8,959|241,369|244,142| ## |PRIOR|YEAR COIVIPARATIVE|||||| |---|---|---|---|---|---|---| ||||Support|Governance|Total|Total| ||||costs|costs|2021|2020| ||||f|E|f|f| ||SUPPORT AND GOVERNANCE|COSTS||||| ||Staff costs (note 6)|||691|691|1,490| ||Other expenditure:|||||| ||Operating
lease rentals:|||||| ||Land and buildings||136,747||136,747|145,620| ||Other premises costs||15,854||15,854|20,810| ||Auditors'
remuneration:|||||| ||Audit fees|||10,288|10,288|10,000| ||Bookkeeping
and payroll costs||10,920|166|11,086|26,217| ||Public relations||447|7|454|| ||Computer
expenses||30,0660|467|31,127|30,111| ||Insurance||17,370|265|17,635|17,077| ||Sundry expenses||4,183|64|4,247|13,063| ||Telephone||4,468|68|4,536|2,832| ||Office costs||5,319|81|5,400|10,877| ||Steering Group|||||3,837| ||Trustee expenses|||||3,042| ||Depreciation
-owned assets||5,849|85|5,934|5,640| ||Bank charges||143||143|88| ||||231,960|12,181|244,142|290,704| |||||2022|2021| |---|---|---|---|---|---| |STAFF COSTS|||||| |||||No.|No.| |The average monthly|number ofpersons employed||by||| |NCEPOD during the year (excluding Trustees) was:|||||| |Designing
and running|ofconfidential|surveys||14|14| |Staff costs for the above persons:|||||| |Wages and salaries
Social security costs||||480,526
47,322|434,049
38,975| |Pension costs||||47,252|43,025| |||||575,100|516,049| |Staff costs are allocated
in the financial statements,|||as follows:||| |Designing
and running
Governance
costs|of confidential|surveys —unrestricted||574,354
746|515,358
691| |||||575,100|516,049| ## |||Computer|Fixtures &|| |---|---|---|---|---| |||equipment
f|fittings
f|TOTAL
f| |Cost:||||| |1April 2021||30,351|15,033|45,384| |Additions||504||504| |Disposals||||| |31March 2022||30,855|15,033|45,888| |Depreciation:||||| |1April 2021||27,208|14,884|42,092| |Charge
in the year||2,809|149|5,934| |Depreciation
on disposal||||| |31March 2022||30,017|15,033|42,092| |Net book value:||||| |31March 2022||838||838| |31March 2021||3,143|149|3,292| ||||2022|2021| |INVESTMENTS||||| |Listed investments:||||| |Opening
balance at 1|April||212,538|151,957| |Additions at cost||||200,637| |(inc cash account movement)||||| |Disposals||||(174,875)| |Realised gains/losses|in investments|||22,918| |Unrealised
gains/losses
on investments|||11,311|11,902| |Market value at 31March|||223,849|212,538| |||||2022|2021| |---|---|---|---|---|---| ||Analysis ofinvestment|holdings|||| ||QC Global income and|Growth|Fund|223,849|212,538| ||Market value at31March|||223,849|212,538| ||DEBTORS||||| ||Amounts
falling due within one||year:||| ||Trade debtors|||304,871|287,351| ||Other debtors|||24,643|25,645| ||Prepayments|||46,825|42,761| |||||376,339|355,757| |10.|CREDITORS||||| ||Amounts
falling due within one||year:||| ||Trade creditors|||7,752|35,268| ||Accruals and deferred|income||163,914|112,357| |||||171,666|147,625| ||Deferred income||||| ||Deferred income at 1|April 2021||88,000|| ||Resources deferred
during the||year|22,000|88,000| ||Amounts
released from previous years||||| |||||110,000|88,000| ## ||||1April|Income|Expenditure|Gain on|31March| |---|---|---|---|---|---|---|---| ||||2021|||Investment|2022| ||||f|||E|f| |Unrestricted||income|funds:||||| |General|Fund||1,495,571|1,383,512|(1,216,165)|11,311|1,664,229| |Designated||Premises|20,000||||30,000| |Fund|||||||| ||||1,515,571|1,383,512|(1,216,165)|11,311|1,694,229| |||||1April|Income|Expenditure|Gain on|31March| |---|---|---|---|---|---|---|---|---| |||||2020|||Investment|2021| |||||E|||E|f| |Unrestricted||income|funds:|||||| |General|Fund|||1,256,343|1,176,656|(972,247)|34,820|1,495,571| |Designated||Premises||20,000||||20,000| |Fund||||||||| |||||1,276,343|1,176,656|(972,247)|34,820|1,515,571| ## ## ||||Fixed asset|Tangible fixed|Net current|Total| |---|---|---|---|---|---|---| ||||investments|assets|assets|| |Unrestricted|income|funds:||||| |General
Fund|||223,849|838|1,449,542|1,664,229| |Designated|Premises|Fund|||20,000|30,000| |NET ASSETS|AT31MARCH 2022||223,849|838|1,469,542|1,694,229| ||||Fixed asset|Tangible fixed|Net current|Total| ||||investments|assets|assets|| |Unrestricted|income|funds:||||| |General
Fund|||212,538|3,292|1,279,741|1,495,571| |Designated|Premises|Fund|||20,000|20,000| |NET ASSETS|AT31MARCH 2021||212,538|3,292|1,299,741|1,515,571| ## ## ||||2022|2021| |---|---|---|---|---| ||||E|E| |Net income for the|year||178,659|239,228| |Depreciation
(note|7)||2,959|5,934| |(Gains) on investments|||(11,311)|(34,820)| |Interest from investment|||(6,741)|(10,303)| |Decrease (Increase)|in debtors||(20,582)|5,639| |(Decrease) increase|in creditors||24,039|132,528| |Net cash from operating||activities|167,023|338,206| ## ## ## |At 31March 2022, NCEPOD
operating
leases:|had future
minimu|m
lease paymen|ts
under non-cancellabl|e| |---|---|---|---|---| ||2022||2021|| ||Land & Building|Equipment|Land Ik Building|Equipment| |Within 1year|E69,323|E5,606|E142,000|E5,606| |Within 2-5years||E22,424|E71,000|E1,402| |Total|f69,323|E28,030|E213,000|E7,008| |NET DEBT RECONCILIATION||||| ||At 1|April 2021|Cash flows
At 31March 2022|| |||E||| |Cash at bank and in hand||1,091,609|173,260|1,264,869| |Debt||||| |Total||1,091,609|173,260|1,264,869| |ANALYSIS OF CASH AND CASH EQUIVALENTS||||| |||2022|2021|| |||f|E|| |Cash in hand||1,264,869|1,091,609|| |Total cash and cash equivalents||1,264,869|1,091,609||